417P Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer (Record no. 85201)

000 -LEADER
fixed length control field 02759nab a22003257a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201201b2020 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Kumar A
245 ## - TITLE STATEMENT
Title 417P Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc 2020
300 ## - PHYSICAL DESCRIPTION
Extent
500 ## - GENERAL NOTE
General note Abstract Book of the ESMO Asia Virtual Congress 2020 20-22 November 2020
520 ## - SUMMARY, ETC.
Summary, etc Background
Lung Cancer is a disease with diversity. ALK and ROS1 positive lung cancer constitute one end of the spectrum with a favorable outcome. Lorlatinib has been approved in November,2018 for disease progressing on first and second line ALK inhibitor. We are presenting the outcome data of Lorlatinib in subsequent lines of therapy.
Methods
We retrospectively collected data from Medical Oncology department for ALK and ROS1 positive patients who received lorlatinib post progression on initial therapy.The demographic details, histology, prior treatment, clinical and radiological response, date of disease progression, date of death and toxicity data were collected.We included patients who were started on treatment on 31st December,2019 or earlier.
Results
There were 41 patients in the database who received Lorlatinib.The median age was 47 years (range 23-68 ), with 54% being male. Forty one percent patients have comorbidities; the most common being hypertension and diabetes and 81% patients were of ECOG-PS-1. Three patients were ROS1 positive. Twenty four patients (59%) received two prior TKIs. The most common site of metastasis before starting Lorlatinib were brain(59%) and bone(57%).All patient except one received prior WBRT with 4 being irradiated twice. The median follow up period was 16 months (95% CI: 14.4-17.5).Seventy three percent showed clinical response to therapy with median PFS and OS of 16 months (95% CI 14.0-18.2) and 23 months (95% CI 14.6-31.3) respectively. The most common site of progression was lung (67%) and pleural effusion(33%). Ten out of eighteen patient who progressed received subsequent therapy. The most common grade 3 and above toxicity were hypercholesterolemia and hypertriglyceridemia. Three patients underwent dose reduction.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Lung Cancer
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Therapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medical Oncology
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Patients
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Noronha V
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Patil VM
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Joshi AS
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Menon NS
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kapoor A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kumar R
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Mahajan A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Janu A
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shetty O
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prabhash K
773 ## - HOST ITEM ENTRY
Main entry heading Annals of Oncology
Place, publisher, and date of publication London : Elsevier, 2020
Relationship information Vol. 31, no. (Suppl. 6), p. S1404-S1405.
International Standard Serial Number 0923-7534
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Dept Medical Oncology
Corporate name TMC
Article Type Conference Abstract
Country type International
Added Entry TMH - HBNI
First Author TMH - HBNI
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Barcode Date last seen Koha item type
          Tata Memorial Hospital Tata Memorial Hospital 2020-12-01 AR20512 2020-12-01 Articles

Powered by Koha